BeStock  
Stocks › Medical Devices › PACB

Pacific Biosciences of California PACB

US equityMarket cap rank #3366Medical Devices
$2.72 +$0.02 (+0.74%)
Pre-market · Oct 8, 8:20 am ET · After hours $2.70 -0.74%
Open$2.62
Prev close$2.70
Day range$2.50 – $2.74
Volume20.37M
Market cap$845.46M
P/E (TTM)–
Dividend yield–

Earnings

Average move on report day±9.1%last 16 reports
Closed higher6 of 1638% of the time
Best reaction+25.0%
Worst reaction-14.5%

Stock move on the day after each report

-13.1%2023/Q3-13.9%2023/Q4+2.9%2024/Q1+9.2%2024/Q2-6.1%2024/Q3+25.0%2024/Q4-6.7%2025/Q1+7.1%2025/Q2-7.0%2025/Q3-7.1%2025/Q4-14.5%2026/Q1-10.4%2026/Q2
QuarterReport dateTimingImplied moveActual moveVersus implied
2026/Q25 Aug 2026After Market–-10.38%–
2026/Q17 May 2026After Market±14.5%-14.55%Bigger than priced
2025/Q412 Feb 2026After Market±19.0%-7.07%Within range
2025/Q35 Nov 2025After Market±17.0%-7.05%Within range
2025/Q27 Aug 2025After Market±24.4%+7.14%Within range
2025/Q18 May 2025After Market±34.7%-6.67%Within range
2024/Q413 Feb 2025After Market±27.3%+25.00%Within range
2024/Q37 Nov 2024After Market±36.4%-6.12%Within range
2024/Q27 Aug 2024After Market±41.8%+9.15%Within range
2024/Q19 May 2024After Market±32.5%+2.91%Within range
2023/Q415 Feb 2024After Market±24.9%-13.94%Within range
2023/Q330 Oct 2023After Market±24.9%-13.08%Within range
2023/Q22 Aug 2023After Market±13.9%-7.99%Within range
2023/Q12 May 2023After Market±14.8%+3.98%Within range
2022/Q416 Feb 2023After Market±12.9%-3.24%Within range
2022/Q37 Nov 2022After Market±19.3%+7.24%Within range

"Implied move" is the size of move the options market was pricing ahead of the report. Move is the stock’s change on the first session after the release.

Where the revenue comes from

Quarter 2026/Q2

By business line

  • Consumable revenue$20.11M 51.6%
  • Instrument revenue$12.84M 32.9%
  • Service and other revenue$6.06M 15.5%

Fundamentals

Full statements →

Latest reported quarter: Q2, ended Jun 2026

Revenue$39.01M-1.9% YoY
Operating profit-$44.61M+0.5% YoY
Net profit-$44.74M-6.7% YoY
Diluted EPS-$0.14+0.0% YoY
Free cash flow-$39.19M-31.0% YoY
Operating cash flow-$35.58M

Revenue, last 8 quarters

$40.0MSep '24$39.2MDec '24$37.2MMar '25$39.8MJun '25$38.4MSep '25$44.6MDec '25$37.2MMar '26$39.0MJun '26

Net profit, last 8 quarters

$-60.7MSep '24$2.4MDec '24$-426.1MMar '25$-41.9MJun '25$-38.0MSep '25$-40.4MDec '25$-8.3MMar '26$-44.7MJun '26

Profitability & balance sheet

Gross margin36.4%
Operating margin-102.6%
Net margin-82.5%
Return on equity-929.3%
Return on assets-16.7%
Return on invested capital-17.7%
Current ratio4.92
Liabilities / assets104.4%
Cash & investments$236.87M
Total debt$704.76M
Net cash (debt)-$467.88M

Discussion

No comments yet — be the first to weigh in on PACB.

Leave a comment

Scroll to Top